Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 45 - Medicinal preparations containing active ingredients not provided for in groups
Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
12/2005
12/21/2005CN1711089A Combination administration of an indolinone with a chemotherapeutic agent for cell proliferation disorders
12/21/2005CN1711076A Combination cancer therapy with a GST-activated anticancer compound and another anticancer therapy
12/21/2005CN1709510A Vaccine composition containing modified dendritic cells
12/21/2005CN1709509A Car-sickness medicine
12/21/2005CN1709508A Use of acetylcholinesterase inhibitor for preparing diabetes medicines
12/21/2005CN1709507A External-application compound hemostatic analgesia anti-inflammation medicine
12/21/2005CN1232643C Nucleic acid vaccine
12/21/2005CN1232518C Bi-heterocyclic compounds with antitumour and chemosensitising activity
12/21/2005CN1232507C Growth hormone secretagogues
12/21/2005CN1232306C Adjustable controllable tumor living vaccine and its preparation method
12/21/2005CN1232261C Peritoneal dialysates and its preparing method
12/21/2005CN1232252C Retard release preparation containing alpha-lipoic acid (derivatives)
12/21/2005CA2510220A1 Heparin barrier coating for controlled drug release
12/20/2005US6977263 Chemical compounds
12/20/2005US6977252 Use of 1,4-benzothiazepine derivatives as drugs for overcoming resistance to anticancer drugs
12/20/2005US6977150 Process and compositions for peptide, protein and peptidomimetic synthesis
12/20/2005US6977147 Method of screening therapeutic or preventative agents for squamous epithelial cell carcinoma
12/20/2005US6977080 administering intrapericardially a neurotoxin; reducing the previously required daily antiarrhythmic drug, reducing need for pacemakers
12/20/2005US6977072 Unblocking immunization at a regional lymph node by: promoting differentiation and maturation of immature dendritic cells in a regional lymph node and; allowing presentation by resulting mature dendritic cells of antigen to T-cells
12/20/2005CA2338206C High affinity ligands for nociceptin receptor orl-1
12/18/2005WO2007049098A2 Therapeutic formulations for the treatment of beta-amyloid related diseases
12/18/2005CA2582385A1 Therapeutic formulations for the treatment of beta-amyloid related diseases
12/18/2005CA2509049A1 Production of mutant strain of aspergillus fumigatus, method and assay for inhibiting siderophore biosynthesis and diagnostic method for detecting likely aspergillus fumigatus infection
12/18/2005CA2472695A1 Production of mutant strain of aspergillus fumigatus and method and assay for inhibiting siderophore biosynthesis
12/16/2005CA2505103A1 Nutritional supplement for adults
12/16/2005CA2505043A1 Nutritional supplement for infants
12/15/2005WO2005119261A2 Glut5 transporters expressed in cancer cells
12/15/2005WO2005118811A1 Novel polypeptide useful for diagnosis and treatment of cancer
12/15/2005WO2005118631A1 Novel protein complex and use thereof
12/15/2005WO2005118543A1 Kinase inhibitor and use thereof
12/15/2005WO2005118009A2 Transdermal delivery system for treatment of cognitive disorders
12/15/2005WO2005117981A1 Formulations comprising a capsaicinoid a local anesthetic and/or an antipruritic agent for the treatment of pain
12/15/2005WO2005117980A1 Method for treating abnormal cell growth
12/15/2005WO2005117979A2 Use of il-17 in the treatment of fertility-related disorders
12/15/2005WO2005117954A2 Compositions and methods for treatment of neovascular diseases
12/15/2005WO2005117935A1 Multiple agent therapy for sexual dysfunction
12/15/2005WO2005117924A1 Compositions and methods using same for treating neurodegenerative disorders
12/15/2005WO2005117912A1 Methods for treating bleeding disorders using sulfated polysaccharides
12/15/2005WO2005117895A2 Compositions comprising meloxicam
12/15/2005WO2005117877A1 Treatment with irinotecan (cpt-11) and an egfr-inhibitor
12/15/2005WO2005117872A2 Dual acting snri-nmda antagonists for the treatment of genitourinary disorders
12/15/2005WO2005117854A2 Aryl ketone compounds and compositions for delivering active agents
12/15/2005WO2005117853A1 Therapeutic agent for hyperlipemia and therapeutic agent for diabetes
12/15/2005WO2005117532A2 Method for improved breast milk feeding to reduce the risk of allergy
12/15/2005WO2005094305A3 Combination therapy for weight management
12/15/2005WO2005084230A3 Synergistic anti-inflammatory pharmaceutical compositions and related methods using curcuminoids or methylxanthines
12/15/2005WO2005079848A3 Agonists and antagonists of p28 ebi3 and wsx/tccr for treating immune disorders
12/15/2005WO2005072764A3 Fibrin-bound angiogenic factors to stimulate vascularization of transplant site of encapsulated cells
12/15/2005WO2005070459A8 Method of continuing expression of vector repeatedly administered
12/15/2005WO2005062874A3 Compounds and compositions for delivering active agents
12/15/2005WO2005058288A3 Antimicrobial article with diffusion control layer
12/15/2005WO2005021706A3 Delivery of compounds with rehydrated blood cells
12/15/2005WO2004101764A3 Methods of modulating metastasis and skeletal related events resulting from metastases
12/15/2005WO2004066931A3 Composition for and treatment of demyelinating diseases and paralysis by administration of remyelinating agents
12/15/2005WO2004014313A3 Combination pharmaceutical agents as inhibitors of hcv replication
12/15/2005WO2003063759A3 Hsp peptides and analogs for modulation of immune responses via antigen presenting cells
12/15/2005US20050277686 Benzimidazole compounds for regulating IgE
12/15/2005US20050277626 Methods and compositions for treatment of nicotine dependence and dementias
12/15/2005US20050277618 Methods
12/15/2005US20050277609 Immunostimulatory nucleic acid molecules
12/15/2005US20050277604 Immunostimulatory nucleic acid molecules
12/15/2005US20050277596 Use of lacosamide; motor neuron disorders
12/15/2005US20050277585 Combinations of immunosupressive agents for the treatment or prevention of graft rejections
12/15/2005US20050277165 Novel treatment
12/15/2005US20050276974 Phospholipid-free, having a D50 particle size of less than 500 nm, andhaving a surface stabilizer; improved pharmacokinetic profiles and reduced fed/fasted variability
12/15/2005US20050276861 Ex-vivo application of solid microparticulate therapeutic agents
12/15/2005US20050276854 Bioimplant formulation
12/15/2005US20050276839 Appetite satiation and hydration beverage
12/15/2005US20050276830 Compounds, formulations, and methods for treating or preventing inflammatory skin disorders
12/15/2005US20050276803 Method for augmenting B cell depletion
12/15/2005US20050276798 with a histidine buffer and maltose; anti-HIV; higher concentrations, are storage stable, compatible with lyophilization, and safe to administer by intravenous injection
12/15/2005US20050276795 Chemotherapeutic and prophylactic pharmaceutical compositions
12/15/2005US20050276794 Composition and method for improving pancreatic islet cell survival
12/15/2005US20050276792 Systems and methods for providing a stem cell bank
12/15/2005US20050276791 Multi-layer polymer scaffolds
12/15/2005US20050276786 Locally administering to tumor antigen-releasing agent, tumor leukocyte attractant and tumor interferon-gamma (IFN-g), and second type 1 inflammatory response-(IR1-)promoting agent for tumor therapy
12/15/2005US20050276756 Compositions as adjuvants to improve immune responses to vaccines and methods of use
12/15/2005CA2709865A1 Method for improved breast milk feeding to reduce the risk of allergy
12/15/2005CA2569277A1 Method for treating abnormal cell growth
12/15/2005CA2569155A1 Formulations comprising a capsaicinoid a local anesthetic and/or an antipruritic agent for the treatment of pain
12/15/2005CA2568750A1 Compositions and methods for treatment of neovascular diseases
12/15/2005CA2568218A1 Multiple agent therapy for sexual dysfunction
12/15/2005CA2567495A1 Methods for treating bleeding disorders using sulfated polysaccharides
12/15/2005CA2566971A1 Treatment with irinotecan (cpt-11) and an egfr-inhibitor
12/15/2005CA2566518A1 Compositions and methods using same for treating neurodegenerative disorders
12/15/2005CA2566161A1 Aryl ketone compounds and compositions for delivering active agents
12/15/2005CA2565801A1 Use of il-17 in the treatment of fertility-related disorders
12/15/2005CA2560472A1 Method for improved breast milk feeding to reduce the risk of allergy
12/14/2005EP1605053A1 Use of adenoviruses mutated in the VA genes for cancer treatment
12/14/2005EP1604686A1 Use of phenserine and a HMG CoA reductase inhibitor for delaying Alzheimer's disease progression
12/14/2005EP1604681A1 Use of botulinum toxin in the treatment of joint pain
12/14/2005EP1604680A1 Use of botulinum toxin in the treatment of neuralgia pain
12/14/2005EP1604679A1 Use of botulinum toxin in the treatment of visceral pain
12/14/2005EP1604678A1 Use of botulinum toxin in the treatment of post-operative pain
12/14/2005EP1604677A1 Composition having antioxidant, anti-inflammatory, and immunostimulant actions
12/14/2005EP1604664A1 Medicine for prevention of and treatment for arteriosclerosis and hypertension
12/14/2005EP1604658A2 Pharmaceutical composition comprising ibuprofen and prochlorperazine
12/14/2005EP1604656A1 Novel use of peptide compounds for treating amyotrophic lateral sclerosis (ALS)
12/14/2005EP1604653A1 Acetylcholinesterase inhibitors for improving excretory potency of urinary bladder
12/14/2005EP1604652A2 Topical anaesthetic preparation for pretreatment for upper gastrointestinal endoscopy
1 ... 435 436 437 438 439 440 441 442 443 444 445 446 447 448 449 450 451 452 453 454 455 ... 1151